TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03189641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cilostazol eluting stent system (CES-1)
Description: Implantation of drug eluting stent
Study: NCT00740298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: sweet taste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warmth
Description: warmth
Study: NCT02145442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Obex
Description: Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
Study: NCT02237508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Study: NCT01403688

Intervention type: PROCEDURE
Intervention: RPFNA
Description: 1. Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~2. Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~3. Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding
Study: NCT03025815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: sham stimulation program consists of the same researcher placing her hands for 15 minutes.
Study: NCT03376256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compuflo Epidural Instrument
Description: Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compuflo Epidural Instrument
Description: Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
Study: NCT01527695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER tablet 25 mg AZD3241
Description: 2 tablets twice daily for Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER tablet 100 mg AZD3241
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for AZD3241 25 mg
Description: 2 tablets twice daily for Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for AZD3241 100 mg
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Study: NCT03957473

Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
Study: NCT04723628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (telephone counseling)
Description: Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
Study: NCT00812981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1562902A
Description: new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1562902A
Description: comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
Study: NCT02237508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Study: NCT02227316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Description: Uterine fibroid embolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Description: Uterine fibroid embolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Uterine fibroid embolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Uterine fibroid embolization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous placebo/Intravenous placebo
Description: Uterine fibroid embolization
Study: NCT03877458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088
Description: Taking 1 mix probiotics capsule at bed time everyday for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. reuteri GL-104
Description: Taking 1 probiotic capsule at bed time everyday for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 placebo capsule at bed time everyday for three months.
Study: NCT04491812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Elastic Kinesiology Tape

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy program
Description: designed physical therapy program
Study: NCT04096040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: μCor
Description: μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
Study: NCT03837626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: 6 months of 1 pill a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride Pill
Description: Max dose of 5 mg a day for 6 months
Study: NCT03719859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Therapy
Description: The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
Study: NCT03663569

Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: Drug
Study: NCT03233191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Mammography
Description: Undergo DM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo TM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02974998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HTC
Description: Participants received the standard HTC available in South Africa for this population.
Study: NCT00954226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00526357

Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acid
Description: Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)

Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acid
Description: Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
Study: NCT04937933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Description: The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution
Study: NCT00090220

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo intramuscular injection in three 0.5 mL doses over 6 months.
Study: NCT04598035

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Tests
Description: 1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Tests
Description: 1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain
Study: NCT04048551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
Study: NCT04168021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg ischemia
Description: potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
Study: NCT01482065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP (ResMed S9 autoset CPAP)
Description: A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI\> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
Study: NCT02314260

Intervention type: OTHER
Intervention: bishop score calculation
Description: Assessment of bishop score by vaginal examination

Intervention type: OTHER
Intervention: Trans-vaginal ultrasound
Description: trans-vaginal ultrasound assessment of cervical length.

Intervention type: OTHER
Intervention: Modified bishop score calculation
Description: using the cervical length and the original bishop score to calculate modified bishop score

Intervention type: PROCEDURE
Intervention: labour induction
Description: Induction of labor was carried out as per our hospital's standard protocol.
Study: NCT00800774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
Study: NCT04048551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
Study: NCT05704062

Intervention type: PROCEDURE
Intervention: Diffusion Weighted Imaging
Description: Undergo DW-MRI

Intervention type: PROCEDURE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI
Study: NCT03520153

Intervention type: PROCEDURE
Intervention: Hyperinsulinemic Euglycemic Clamp and 2H20
Description: Test is used to assess insulin effects on hepatic glucose production.
Study: NCT02965014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Young Women's CoOp (YWC)
Description: Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Young Women's CoOp (YWC)
Description: Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling and Testing
Description: Participants will be offered standard HIV counseling and testing (HCT).
Study: NCT04734548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ApTOLL
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ApTOLL
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
Study: NCT04641442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAS825
Description: Experimental drug

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo